GlassScriptPhysician profile
Samuel Ng
NPI 1619439262
$3,256.12
in general payments reported to CMS, 2019-2025
20 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $710 · 2024: $1,278 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,256.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $636.32 | 2023-2025 | |
| Glaxosmithkline, LLC. | $614.76 | 2023-2025 | Benlysta |
| Amgen INC. | $585.11 | 2023-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $228.67 | 2024-2025 | Saphnelo |
| Ucb, INC. | $217.25 | 2024-2025 | Cimzia, Bimzelx |
| Ani Pharmaceuticals, INC. | $149.23 | 2025 | Purified Cortrophin Gel |
| Janssen Biotech, INC. | $131.32 | 2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $126.48 | 2024-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $115.64 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.25 | 2023-2024 | Ofev, Cyltezo |
| Genentech USA, INC. | $103.97 | 2023-2025 | Actemra |
| Organon LLC | $31.94 | 2025 | Hadlima |
| Sanofi-Aventis U.S. LLC | $31.83 | 2023 | |
| Sobi, INC | $30.82 | 2025 | |
| Lilly USA, LLC | $30.50 | 2025 | Taltz |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $25.88 | 2024 | Uptravi, Opsumit |
| Pfizer INC. | $24.71 | 2024 | |
| Genzyme Corporation | $22.57 | 2024 | |
| Janssen Scientific Affairs, LLC | $21.51 | 2025 | |
| Aurinia Pharma U.S., INC. | $14.36 | 2024 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.